Ollin Biosciences valuation, funding and investors
Ollin Biosciences is a pharmaceutical products company based in Austin, United States. Founded in 2023, it has about 28 employees.
- Last round
- Series B · $330M · Jun 2026
- Valuation at last round
- $1.71B · implied
- Headcount
- 28
- Grade
- B
- Founded
- 2023
Ollin Biosciences valuation today
VCMC values Ollin Biosciences at $2.0B today, with a range of $1.2B to $3.6B and a grade of B. The valuation starts from its last funding round, a Series B round in Jun 2026.
Valuation by date (49 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2023 | $20.8M | $7.56M – $57.0M | $22.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2023 | $20.9M | $7.62M – $57.5M | $22.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2023 | $21.1M | $7.67M – $57.9M | $23.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2023 | $21.2M | $7.73M – $58.3M | $23.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2023 | $21.4M | $7.78M – $58.7M | $23.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2023 | $21.5M | $7.84M – $59.2M | $23.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2023 | $21.7M | $7.90M – $59.6M | $23.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2023 | $21.9M | $7.96M – $60.0M | $23.7M (+8%) | before first round | – | unknown | D | 0% |
| 1 Sep 2023 | $22.0M | $8.02M – $60.5M | $23.7M (+8%) | before first round | – | unknown | D | 0% |
| 1 Oct 2023 | $22.2M | $8.07M – $60.9M | $23.7M (+7%) | before first round | – | unknown | D | 0% |
| 1 Nov 2023 | $22.3M | $8.13M – $61.4M | $23.7M (+6%) | before first round | – | unknown | D | 0% |
| 1 Dec 2023 | $22.5M | $8.19M – $61.8M | $23.7M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2024 | $22.7M | $8.26M – $62.3M | $23.7M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2024 | $22.8M | $8.32M – $62.8M | $23.7M (+4%) | before first round | – | unknown | D | 0% |
| 1 Mar 2024 | $23.0M | $8.38M – $63.2M | $23.7M (+3%) | before first round | – | unknown | D | 0% |
| 1 Apr 2024 | $23.2M | $8.44M – $63.7M | $23.7M (+2%) | before first round | – | unknown | D | 0% |
| 1 May 2024 | $23.4M | $8.50M – $64.1M | $23.7M (+1%) | before first round | – | unknown | D | 0% |
| 1 Jun 2024 | $23.5M | $8.56M – $64.6M | $23.7M (+1%) | before first round | – | unknown | D | 0% |
| 1 Jul 2024 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2024 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2024 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Oct 2024 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Nov 2024 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Dec 2024 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Jan 2025 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Feb 2025 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Mar 2025 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Apr 2025 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 May 2025 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Jun 2025 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Jul 2025 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Aug 2025 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 1 Sep 2025 | $23.7M | $8.63M – $65.1M | $23.7M (0%) | before first round | – | unknown | D | 0% |
| 18 Sep 2025 | $556M | $365M – $1.5B | $1.0B (+80%) | after a round | – | unknown | C | 0% |
| 1 Oct 2025 | $568M | $365M – $1.5B | $1.0B (+76%) | after a round | – | unknown | C | 0% |
| 1 Nov 2025 | $597M | $365M – $1.5B | $1.0B (+67%) | after a round | – | unknown | C | 0% |
| 1 Dec 2025 | $627M | $365M – $1.5B | $1.0B (+60%) | after a round | – | unknown | C | 0% |
| 1 Jan 2026 | $659M | $365M – $1.5B | $1.0B (+52%) | after a round | – | unknown | C | 0% |
| 1 Feb 2026 | $693M | $365M – $1.5B | $1.0B (+44%) | after a round | – | unknown | C | 0% |
| 1 Mar 2026 | $725M | $365M – $1.5B | $1.0B (+38%) | after a round | – | unknown | C | 0% |
| 1 Apr 2026 | $762M | $365M – $1.5B | $1.0B (+31%) | after a round | – | unknown | C | 0% |
| 1 May 2026 | $799M | $365M – $1.5B | $1.0B (+25%) | after a round | – | unknown | C | 0% |
| 1 Jun 2026 | $840M | $365M – $1.5B | $1.0B (+19%) | after a round | – | unknown | C | 0% |
| 25 Jun 2026 | $1.7B | $1.2B – $3.6B | $2.6B (+50%) | after a round | – | unknown | B | 0% |
| 1 Jul 2026 | $1.7B | $1.2B – $3.6B | $2.6B (+49%) | after a round | – | unknown | B | 0% |
| 1 Aug 2026 | $1.8B | $1.2B – $3.6B | $2.6B (+44%) | after a round | – | unknown | B | 0% |
| 1 Sep 2026 | $1.8B | $1.2B – $3.6B | $2.6B (+39%) | after a round | – | unknown | B | 0% |
| 1 Oct 2026 | $1.9B | $1.2B – $3.6B | $2.6B (+34%) | after a round | 28 | unknown | B | 0% |
| 24 Oct 2026 | $2.0B | $1.2B – $3.6B | $2.6B (+31%) | after a round | 28 | unknown | B | 0% |
Key facts about Ollin Biosciences
- Founded
- 2023
- Headquarters
- Austin, United States
- Employees
- about 28
- Total raised
- $430M
- Funding rounds
- 2
- Last round
- Series B Jun 2026
Ollin Biosciences funding history
Ollin Biosciences has 2 funding rounds on record, from Sep 2025 to Jun 2026, $430M in total. None disclosed a valuation.
Series B 24 Jun 2026
Led by TCG Crossover, ARCH Venture Partners; with Andreessen Horowitz, Blackstone, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital, T. Rowe Price Investment Management, Inc., Mubadala Capital, Monograph Capital.
Sources: ollin.bio, prnewswire.com, fiercebiotech.com and 3 more
$330M
Series A 17 Sep 2025
Led by ARCH Venture Partners, Mubadala Capital, Monograph Capital.
Sources: excedr.com, ophthalmologytimes.com, eyewire.news
$100M
Ollin Biosciences investors
10 investors have backed Ollin Biosciences; ARCH Venture Partners, Monograph Capital and Mubadala Capital and 1 more led at least one round.
- ARCH Venture Partners lead, 2 rounds
- Mubadala Capital lead, 2 rounds
- Andreessen Horowitz
- Blackstone
- Canada Pension Plan Investment Board (CPP Investments)
- T. Rowe Price Investment Management, Inc.
What Ollin Biosciences does
Ollin Biosciences is classified under pharmaceutical products. No offerings or markets are recorded yet.
Ollin Biosciences, Inc. is an American biopharmaceutical company engaged in the development of therapies for vision-threatening diseases, with a primary focus on ophthalmology. The company conducts clinical research and development, including the advancement of bispecific antibodies for conditions such as wet age-related macular degeneration, diabetic macular edema, and thyroid eye disease. Ollin Biosciences also utilizes data science and imaging tools in its therapeutic development.
Description from Veridion's company data.
Questions about Ollin Biosciences
What is Ollin Biosciences worth?
Valuation $2.0B (range $1.2B to $3.6B), as of 24 Oct 2026.
Has Ollin Biosciences raised money?
Ollin Biosciences has 2 funding rounds on record, from Sep 2025 to Jun 2026, $430M in total. None disclosed a valuation.
Who has invested in Ollin Biosciences?
ARCH Venture Partners, Monograph Capital, Mubadala Capital, TCG Crossover, Andreessen Horowitz and Blackstone, and 4 more. Lead investors include ARCH Venture Partners, Monograph Capital, Mubadala Capital and TCG Crossover.
How many people work at Ollin Biosciences?
About 28.
When was Ollin Biosciences founded, and where is it based?
Ollin Biosciences was founded in 2023 and is based in Austin, United States. It has about 28 employees.